title: Surfactant application in experimental lung transplantation.
abstract: BACKGROUND
  Non-heart-beating donor (NHBD) utilization can significantly increase the limited donor lung pool. However, optimal preservation of organ function is crucial as the development of ischemia/reperfusion injury (IRI) can result in severe surfactant inactivation. Exogenic surfactant application is effective in prevention and therapy of IRI. Studies on optimal timing of Curosurf, including application in NHBDs, have not been done, but could help to optimize NHBD lung transplantation.
  
  
  METHODS
  The extracorporeal screening model (ESM) included rat lungs (Sprague-Dawley, n = 5/group) preserved with Perfadex. In 3 test groups, Curosurf was administered before flush preservation (T1), after 4-hour ischemia (T2) or during reperfusion (T3). Results after extracorporeal reperfusion were compared with controls. The transplantation model (TM) consisted of asystolic pigs (n = 5/group) ventilated for 7 hours with warm ischemia (WIT, Groups 1 and 2). In Group 2, 100 mg/kg BW Curosurf was bronchoscopically administered before preservation. After 3-hour cold storage, left lung transplantation was performed and data were compared with sham control data (Group 3).
  
  
  RESULTS
  For the ESM, T1 lung oxygenation (SurfT1 167±47.4 mm Hg) was superior to others (SurfT2 47.3±15.3 mm Hg, SurfT3 77.2±48.8 mm Hg, controls 65.5±46.2 mm Hg; p<0.02). Stereology demonstrated poorer intra-alveolar edema formation in controls (1.86±2.53% of parenchyma) compared with surfactant-treated lungs (<0.02% of parenchyma) (p<0.02). Intra-alveolar erythrocyte sequestration as an indicator of vascular leakage was significantly lower in T1 lungs (0.15±0.12% of parenchyma) compared with all other groups (>0.74% of parenchyma). For TM, mortality was 80% in the untreated group and 100% in the Curosurf group, suggesting that a 7-hour WIT is above the limit for NHBD utilization.
  
  
  CONCLUSIONS
  Donor lung pre-treatment with endobronchial pre-preservation Curosurf offers optimal preservation quality when compared with post-ischemic application or during reperfusion and results in improved functional outcome when compared with controls. Expensive NHBD pre-treatment with Curosurf cannot improve poor allograft outcome after extended WIT and should therefore not be considered. Seven-hour WIT seems generally to be above the limits for use in NHBD lung donors.
authors: Department of Cardiothoracic Surgery, Heart Center, University Hospital of Cologne, Cologne, Germany. th.wittwer-md@t-online.de
authors: Thorsten
authors: T
authors: Wittwer
authors: Navid
authors: N
authors: Madershahian
authors: Parwis
authors: P
authors: Rahmanian
authors: Yeong-Hoon
authors: YH
authors: Choi
authors: Klaus
authors: K
authors: Neef
authors: Konrad
authors: K
authors: Frank
authors: Jochen
authors: J
authors: Müller-Ehmsen
authors: Matthias
authors: M
authors: Ochs
authors: Christian
authors: C
authors: Mühlfeld
authors: Thorsten
authors: T
authors: Wahlers
mesh_terms: D000818:Animals; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D066298:In Vitro Techniques; D016040:Lung Transplantation; D008297:Male; D009926:Organ Preservation / Q000379:methods; D010743:Phospholipids / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D034421:Sus scrofa
chemical_list: D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa